Research never stops


Dec 14, 2009

Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.

Nov 18, 2009

Evotec Wins German Government Research Grant

Nov 12, 2009

Evotec Third Quarter Financial Results

Nov 10, 2009

Evotec to Voluntarily Delist from NASDAQ

Nov 09, 2009

Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration

Oct 22, 2009

Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim

Oct 20, 2009

Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services

Oct 15, 2009

Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd.

Oct 01, 2009

Evotec achieves milestone with Cardioxyl Pharmaceuticals - as compound enters the clinic

Sep 09, 2009

Evotec announces Research Agreement
with Biogen Idec

Sep 08, 2009

Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist

Aug 31, 2009

Evotec completes acquisition of controlling majority stake in Research Support International Private Limited (RSIPL)

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today that the acquisition of the controlling majority stake of Research Support International Private Limited ("RSIPL") has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

- read more
Aug 07, 2009

Evotec Announces Strong Second Quarter Financial Results

Aug 06, 2009

Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL

Jul 30, 2009

Evotec to Report First Half 2009 Results on August 7, 2009

Jul 29, 2009

Evotec Receives Milestone Payment from Boehringer Ingelheim

Jul 21, 2009

Evotec Signs High Throughput Screening Collaboration with Alios Biopharma, Inc

Jul 14, 2009

Evotec announces Research Agreement on Fragment- Based Drug Discovery with Cubist Pharmaceuticals

Jul 07, 2009

Evotec-RSIL Ltd extends library synthesis collaboration with Ferrer Grupo

Jun 29, 2009

Evotec Announces the Successful Completion of the First Phase I Study with EVT 401, an Oral P2X7 Receptor Antagonist - Very Good Safety Profile and Confirmed "On Target Activity"

Jun 24, 2009

Evotec Strengthens its Ion Channel Capabilities To Support New Alliances

May 12, 2009

Evotec Announces First Quarter Results and Corporate Development Update

May 07, 2009

Evotec Acquires Zebrafish Screening Operations of Summit Corporation

May 05, 2009

Evotec to Re-engineer Drug Discovery and Development Operations

Apr 27, 2009

Walter Wenninger Nominated for Election as New Supervisory Board Member of Evotec

Apr 14, 2009

Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302

Mar 27, 2009

Evotec Restructures and Implements "Evotec 2012 - Action Plan to Focus and Grow"

Mar 27, 2009

Evotec Announces Financial Results for 2008

Mar 09, 2009

Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression

Mar 06, 2009

Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer